Reply

AsthmaNet Investigators

doi:10.1016/j.jaci.2019.05.029

Reply

AsthmaNet Investigators

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	873-874
Number of pages	2
Journal	Journal of Allergy and Clinical Immunology
Volume	144
Issue number	3
DOIs	https://doi.org/10.1016/j.jaci.2019.05.029
State	Published - Sep 2019

Access to Document

10.1016/j.jaci.2019.05.029

Cite this

@article{419529b640794613b539f71a4d2de083,

title = "Reply",

author = "{AsthmaNet Investigators} and Cardet, {Juan Carlos} and Xiaofeng Jiang and Quan Lu and Norma Gerard and Kristen McIntire and Boushey, {Homer A.} and Mario Castro and Chinchilli, {Vernon M.} and Codispoti, {Christopher D.} and Dyer, {Anne Marie} and Fernando Holguin and Monica Kraft and Stephen Lazarus and Lemanske, {Robert F.} and Njira Lugogo and Dave Mauger and Moore, {Wendy C.} and James Moy and Ortega, {Victor E.} and Peters, {Stephen P.} and Smith, {Lewis J.} and Julian Solway and Sorkness, {Christine A.} and Kaharu Sumino and Wechsler, {Michael E.} and Sally Wenzel and Elliot Israel",

note = "Funding Information: Supported by grants HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115 awarded by the National Heart, Lung, and Blood Institute.Disclosure of potential conflict of interest: J. C. Cardet reports grants from the National Institute of Allergy and Infectious Diseases (NIAID) during the conduct of the study. M. Castro reports grants from the National Institutes of Health (NIH) and American Lung Association during the conduct of the study and personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GlaxoSmithKline, Holaira, and Teva; grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GlaxoSmithKline, Invion, MedImmune, sanofi-aventis, and Vectura all outside the submitted work. V. M. Chinchilli, S. P. Peters, and S. Lazarus report grants from the NIH/National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. A.-M. Dyer reports grants from the NHLBI during the conduct of the study. M. Kraft reports grants from the NIH, Roche, Sanofi, and Chiesi and other support from TEVA, AstraZeneca, and Elsevier outside the submitted work. R. F. Lemanske reports grants from the NHLBI during the conduct of the study; nonfinancial support from the American Academy of Allergy, Asthma & Immunology (AAAAI); grants from the Clinical and Translational Science Award from the NIH; personal fees from LSU, Elsevier, and UpToDate; and grants from Childhood Origins of Asthma (COAST) and AsthmaNet outside the submitted work. N. Lugogo reports personal fees from AstraZeneca and consulting fees from TEVA, outside the submitted work. D. Mauger reports grants from the NIH during the conduct of the study and nonfinancial support from GlaxoSmithKline, Merck, and TEVA outside the submitted work. W. C. Moore reports grants from the NIH/NHLBI during the conduct of the study, grants and personal fees from AstraZeneca and Sanofi Regeneron, and grants from Boehringer Ingelheim, GlaxoSmithKline, Pearl Therapeutics, and Novartis outside the submitted work. J. Solway reports consulting fees from Sanofi, Genzyme, and Regeneron and gifts from the Rafael Rivera III Memorial Foundation for Asthma Research to the University of Chicago that were designated for asthma research in his laboratory. M. E. Wechsler reports personal fees from AstraZeneca, BSCI, Novartis, Vectura, Regeneron, Genentech, Sentien, and Boehringer Ingelheim and grants and personal fees from Teva, GlaxoSmithKline, and Sanofi, all outside the submitted work. S. Wenzel reports grants and personal fees from AstraZeneca and Sanofi; grants from Boehringer Ingelheim, GlaxoSmithKline, and Novartis; and personal fees from Pieris and UpToDate outside the submitted work. E. Israel reports personal fees from AstraZeneca, Novartis, Philips Respironics, Regeneron Pharmaceuticals, TEVA Specialty Pharmaceuticals, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Sanofi, Merck, Entrinsic Health Solutions, and GlaxoSmithKline; other support from Vorso, Pneuma Respiratory, and 4D Pharma; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, TEVA, and TEVA Specialty Pharmaceuticals outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2019",

month = sep,

doi = "10.1016/j.jaci.2019.05.029",

language = "English",

volume = "144",

pages = "873--874",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

number = "3",

}

TY - JOUR

T1 - Reply

AU - AsthmaNet Investigators

AU - Cardet, Juan Carlos

AU - Jiang, Xiaofeng

AU - Lu, Quan

AU - Gerard, Norma

AU - McIntire, Kristen

AU - Boushey, Homer A.

AU - Castro, Mario

AU - Chinchilli, Vernon M.

AU - Codispoti, Christopher D.

AU - Dyer, Anne Marie

AU - Holguin, Fernando

AU - Kraft, Monica

AU - Lazarus, Stephen

AU - Lemanske, Robert F.

AU - Lugogo, Njira

AU - Mauger, Dave

AU - Moore, Wendy C.

AU - Moy, James

AU - Ortega, Victor E.

AU - Peters, Stephen P.

AU - Smith, Lewis J.

AU - Solway, Julian

AU - Sorkness, Christine A.

AU - Sumino, Kaharu

AU - Wechsler, Michael E.

AU - Wenzel, Sally

AU - Israel, Elliot

N1 - Funding Information: Supported by grants HL098102, U10HL098096, UL1TR000150, UL1TR000430, UL1TR000050, HL098075, UL1TR001082, HL098090, HL098177, UL1TR000439, HL098098, UL1TR000448, HL098107, HL098112, HL098103, UL1TR000454, and HL098115 awarded by the National Heart, Lung, and Blood Institute.Disclosure of potential conflict of interest: J. C. Cardet reports grants from the National Institute of Allergy and Infectious Diseases (NIAID) during the conduct of the study. M. Castro reports grants from the National Institutes of Health (NIH) and American Lung Association during the conduct of the study and personal fees from Aviragen, Boehringer Ingelheim, Boston Scientific, Elsevier, Genentech, GlaxoSmithKline, Holaira, and Teva; grants from Amgen, Boehringer Ingelheim, Genentech, Gilead, GlaxoSmithKline, Invion, MedImmune, sanofi-aventis, and Vectura all outside the submitted work. V. M. Chinchilli, S. P. Peters, and S. Lazarus report grants from the NIH/National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. A.-M. Dyer reports grants from the NHLBI during the conduct of the study. M. Kraft reports grants from the NIH, Roche, Sanofi, and Chiesi and other support from TEVA, AstraZeneca, and Elsevier outside the submitted work. R. F. Lemanske reports grants from the NHLBI during the conduct of the study; nonfinancial support from the American Academy of Allergy, Asthma & Immunology (AAAAI); grants from the Clinical and Translational Science Award from the NIH; personal fees from LSU, Elsevier, and UpToDate; and grants from Childhood Origins of Asthma (COAST) and AsthmaNet outside the submitted work. N. Lugogo reports personal fees from AstraZeneca and consulting fees from TEVA, outside the submitted work. D. Mauger reports grants from the NIH during the conduct of the study and nonfinancial support from GlaxoSmithKline, Merck, and TEVA outside the submitted work. W. C. Moore reports grants from the NIH/NHLBI during the conduct of the study, grants and personal fees from AstraZeneca and Sanofi Regeneron, and grants from Boehringer Ingelheim, GlaxoSmithKline, Pearl Therapeutics, and Novartis outside the submitted work. J. Solway reports consulting fees from Sanofi, Genzyme, and Regeneron and gifts from the Rafael Rivera III Memorial Foundation for Asthma Research to the University of Chicago that were designated for asthma research in his laboratory. M. E. Wechsler reports personal fees from AstraZeneca, BSCI, Novartis, Vectura, Regeneron, Genentech, Sentien, and Boehringer Ingelheim and grants and personal fees from Teva, GlaxoSmithKline, and Sanofi, all outside the submitted work. S. Wenzel reports grants and personal fees from AstraZeneca and Sanofi; grants from Boehringer Ingelheim, GlaxoSmithKline, and Novartis; and personal fees from Pieris and UpToDate outside the submitted work. E. Israel reports personal fees from AstraZeneca, Novartis, Philips Respironics, Regeneron Pharmaceuticals, TEVA Specialty Pharmaceuticals, Bird Rock Bio, Nuvelution Pharmaceuticals, Vitaeris, Sanofi, Merck, Entrinsic Health Solutions, and GlaxoSmithKline; other support from Vorso, Pneuma Respiratory, and 4D Pharma; grants from Genentech, Sanofi, and Boehringer Ingelheim; and nonfinancial support from Boehringer Ingelheim, GlaxoSmithKline, Merck, Sunovion, TEVA, and TEVA Specialty Pharmaceuticals outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2019/9

Y1 - 2019/9

UR - http://www.scopus.com/inward/record.url?scp=85071232529&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2019.05.029

DO - 10.1016/j.jaci.2019.05.029

M3 - Letter

C2 - 31300279

AN - SCOPUS:85071232529

VL - 144

SP - 873

EP - 874

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -

Reply

Access to Document

Other files and links

Cite this